guest ::
| Home > Publications Database > Short-term treatment with flumazenil restores long-term object memory in a mouse model of Down syndrome. > print |
| Home > Publications Database > Short-term treatment with flumazenil restores long-term object memory in a mouse model of Down syndrome. > print |
| 001 | 139181 | ||
| 005 | 20240321220554.0 | ||
| 024 | 7 | _ | |a 10.1016/j.nlm.2017.02.006 |2 doi |
| 024 | 7 | _ | |a pmid:28215510 |2 pmid |
| 024 | 7 | _ | |a 1074-7427 |2 ISSN |
| 024 | 7 | _ | |a 1095-9564 |2 ISSN |
| 037 | _ | _ | |a DZNE-2020-05503 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Colas, Damien |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Short-term treatment with flumazenil restores long-term object memory in a mouse model of Down syndrome. |
| 260 | _ | _ | |a Orlando, Fla. |c 2017 |b Academic Press |
| 264 | _ | 1 | |3 print |2 Crossref |b Elsevier BV |c 2017-04-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1587035958_2267 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Down syndrome (DS) is a common genetic cause of intellectual disability yet no pro-cognitive drug therapies are approved for human use. Mechanistic studies in a mouse model of DS (Ts65Dn mice) demonstrate that impaired cognitive function is due to excessive neuronal inhibitory tone. These deficits are normalized by chronic, short-term low doses of GABAA receptor (GABAAR) antagonists in adult animals, but none of the compounds investigated are approved for human use. We explored the therapeutic potential of flumazenil (FLUM), a GABAAR antagonist working at the benzodiazepine binding site that has FDA approval. Long-term memory was assessed by the Novel Object Recognition (NOR) testing in Ts65Dn mice after acute or short-term chronic treatment with FLUM. Short-term, low, chronic dose regimens of FLUM elicit long-lasting (>1week) normalization of cognitive function in both young and aged mice. FLUM at low dosages produces long lasting cognitive improvements and has the potential of fulfilling an unmet therapeutic need in DS. |
| 536 | _ | _ | |a 341 - Molecular Signaling (POF3-341) |0 G:(DE-HGF)POF3-341 |c POF3-341 |f POF III |x 0 |
| 542 | _ | _ | |i 2017-04-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a GABA Modulators |2 NLM Chemicals |
| 650 | _ | 7 | |a Flumazenil |0 40P7XK9392 |2 NLM Chemicals |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Cognition: drug effects |2 MeSH |
| 650 | _ | 2 | |a Disease Models, Animal |2 MeSH |
| 650 | _ | 2 | |a Down Syndrome: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Down Syndrome: genetics |2 MeSH |
| 650 | _ | 2 | |a Flumazenil: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Flumazenil: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a GABA Modulators: pharmacology |2 MeSH |
| 650 | _ | 2 | |a GABA Modulators: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Memory Disorders: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Memory, Long-Term: drug effects |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 700 | 1 | _ | |a Chuluun, Bayarsaikhan |0 P:(DE-HGF)0 |b 1 |e Corresponding author |
| 700 | 1 | _ | |a Garner, Craig C |0 P:(DE-2719)2810922 |b 2 |e Corresponding author |u dzne |
| 700 | 1 | _ | |a Heller, H Craig |0 P:(DE-HGF)0 |b 3 |e Corresponding author |
| 773 | 1 | 8 | |a 10.1016/j.nlm.2017.02.006 |b : Elsevier BV, 2017-04-01 |p 11-16 |3 journal-article |2 Crossref |t Neurobiology of Learning and Memory |v 140 |y 2017 |x 1074-7427 |
| 773 | _ | _ | |a 10.1016/j.nlm.2017.02.006 |g Vol. 140, p. 11 - 16 |0 PERI:(DE-600)1471414-0 |q 140<11 - 16 |p 11-16 |t Neurobiology of learning and memory |v 140 |y 2017 |x 1074-7427 |
| 909 | C | O | |o oai:pub.dzne.de:139181 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2810922 |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-341 |2 G:(DE-HGF)POF3-300 |v Molecular Signaling |x 0 |
| 914 | 1 | _ | |y 2017 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-17 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEUROBIOL LEARN MEM : 2021 |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-17 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0130 |2 StatID |b Social Sciences Citation Index |d 2022-11-17 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-17 |
| 920 | 1 | _ | |0 I:(DE-2719)1810001 |k AG Garner |l Synaptopathy |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1810001 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|